---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-116720"
form_type: "8-K"
ticker: "MRKR"
cik: "0001094038"
company_name: "Marker Therapeutics, Inc."
filed_at: "2026-10-19T11:12:47+00:00"
generated_at: "2026-10-19T11:15:09.500592+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Marker Therapeutics wins $2.6M FDA orphan grant for MT-601 pancreatic cancer trial

## Summary
- FDA awarded Marker Therapeutics $2.6 million under its Orphan Products Clinical Trials grants program to support a Phase 1 study of MT-601 in locally advanced unresectable pancreatic cancer.
- FDA received 66 applications for the FY2026 orphan products program and selected six, including Marker's MT-601 project.
- Marker plans to initiate the company-sponsored pancreatic cancer study in Q1 2027, using expanded antigen targeting, higher T-cell doses, and lymphodepletion.
- Prior Baylor Phase 1/2 data in Nature Medicine showed 84.6% disease control, 7.5-month median duration of response, and 14.1-month median overall survival.

## SEC filing metadata
- accession: 0001104659-26-116720
- form_type: 8-K
- ticker: MRKR
- cik: 0001094038
- company_name: Marker Therapeutics, Inc.
- filed_at: 2026-10-19T11:12:47+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1094038/000110465926116720/0001104659-26-116720-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1094038/000110465926116720/tm2627740d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-116720
- JSON: https://secwatch.observer/filing/0001104659-26-116720.json
- Plain text: https://secwatch.observer/filing/0001104659-26-116720.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.